{Reference Type}: Journal Article
{Title}: Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
{Author}: Nagaoki Y;Aikata H;Nakano N;Shinohara F;Nakamura Y;Hatooka M;Morio K;Kan H;Fujino H;Kobayashi T;Fukuhara T;Masaki K;Ono A;Nakahara T;Kawaoka T;Miki D;Tsuge M;Hiramatsu A;Imamura M;Takahashi S;Kawakami Y;Ochi H;Chayama K; ;
{Journal}: J Gastroenterol Hepatol
{Volume}: 31
{Issue}: 5
{Year}: May 2016
{Factor}: 4.369
{DOI}: 10.1111/jgh.13236
{Abstract}: <B>BACKGROUND: </B>We assessed the risk factors for the development of hepatocellular carcinoma (HCC) following successful eradication of hepatitis C virus (HCV) with interferon (IFN) therapy in a long-term, large-scale cohort study.<BR><B>METHODS: </B>We reviewed 1094 consecutive patients with HCV who achieved sustained virological response (SVR) following IFN therapy between January 1995 and September 2013.<BR><B>RESULTS: </B>During the observation period (median 50 months: range 13-224), 36 (3%) of 1094 patients developed HCC after SVR. The median period from SVR to diagnosis of HCC was 37 months (range 17-141), and the cumulative rates of HCC at 5, 10, and 15 years were 4%, 6%, and 12%, respectively. Multivariate analysis identified old age (≥60 years, HR, 3.1: 95%CI, 1.3-6.6: P = 0.009), male sex (HR, 12.0: 95%CI, 2.8-50.0: P < 0.0001), advanced fibrosis stage (F3/4, HR, 3.2: 95%CI, 1.6-7.2: P < 0.0001), and alpha-fetoprotein ≥10 ng/mL at 1 year after SVR (HR, 7.8: 95%CI, 2.9-16.8: P < 0.0001) as significant and independent risk factors for post-SVR HCC.<BR><B>CONCLUSIONS: </B>Older age and male sex (host factors), advanced fibrosis stage (pre-IFN treatment factor), and higher alpha-fetoprotein values (post-treatment factor) were significantly associated with HCC development after HCV eradication.